VYNE
VYNE Therapeutics Inc.
Price Chart
Latest Quote
$0.66
-0.01 (-1.35%)
Current Price
| Previous Close | $0.67 |
| Open | $0.65 |
| Day High | $0.67 |
| Day Low | $0.63 |
| Volume | 50,962 |
Stock Information
| Shares Outstanding | 33.35M |
| Cash Equivalents | $24.93M |
| Revenue | $454K |
| Net Income | $-21.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $21.88M |
| EPS (TTM) | $-0.51 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-3.05M |
| Sales | $454K |
| Income | $-21.72M |
| Book/sh | $0.74 |
| Cash/sh | $0.75 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 20.17 |
| Current Ratio | 20.86 |
Returns & Margins
| ROA | -37.01% |
| ROE | -63.16% |
| Gross Margin | 100.00% |
| Operating Margin | -4437.21% |
Ownership
| Insider Ownership | 4.56% |
| Institutional Ownership | 41.71% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.40 |
| P/S | 48.20 |
| P/B | 0.89 |
Analyst Data
| Recommendation | none |
| Target Price | $2.00 |
Technical Indicators
| SMA20 | $0.67 |
| SMA50 | $0.64 |
| SMA200 | $0.50 |
| RSI | 42.22 |
| ATR | 0.0229 |
| Shares Float | 32.55M |
| Short Float | 0.37% |
| Short Ratio | 0.60 |
| Rel Volume | 0.35 |
Performance History
| Week | -3.81% |
| Month | -2.09% |
| Quarter | +10.25% |
| 6 Months | +74.93% |
| YTD | +13.10% |
| Year | -33.74% |
| 3 Years | -89.57% |
| 5 Years | -99.08% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.66 | 51,000 |
| 2026-06-04 | $0.67 | 47,300 |
| 2026-06-03 | $0.66 | 146,300 |
| 2026-06-02 | $0.68 | 73,300 |
| 2026-06-01 | $0.68 | 192,000 |
| 2026-05-29 | $0.68 | 75,100 |
| 2026-05-28 | $0.69 | 71,900 |
| 2026-05-27 | $0.68 | 123,600 |
| 2026-05-26 | $0.68 | 122,400 |
| 2026-05-22 | $0.67 | 78,500 |
| 2026-05-21 | $0.68 | 95,800 |
| 2026-05-20 | $0.68 | 125,000 |
| 2026-05-19 | $0.68 | 146,500 |
| 2026-05-18 | $0.68 | 728,200 |
| 2026-05-15 | $0.67 | 106,400 |
| 2026-05-14 | $0.67 | 110,700 |
| 2026-05-13 | $0.67 | 278,200 |
| 2026-05-12 | $0.66 | 139,500 |
| 2026-05-11 | $0.67 | 123,700 |
| 2026-05-08 | $0.66 | 72,200 |
| 2026-05-07 | $0.67 | 232,600 |
| 2026-05-06 | $0.67 | 189,600 |
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2025-12-17T15:30:18ZVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-06T14:15:04Z
VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. âĸ 2025-08-18T18:37:09Z
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-14T13:15:02Z
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-12T21:40:03Z
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-11T22:55:02Z
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
Zacks âĸ 2025-08-06T22:40:02Z
Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely
Simply Wall St. âĸ 2025-07-31T13:43:38Z
Sector Update: Health Care Stocks Decline in Late Afternoon Trading
MT Newswires âĸ 2025-07-30T19:58:48ZVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress
Insider Monkey âĸ 2025-07-11T23:18:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $570,000 | $501,000 | $424,000 | $477,000 |
| Operating Revenue | $570,000 | $501,000 | $424,000 | $477,000 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $30,319,000 | $44,138,000 | $29,682,000 | $34,772,000 |
| Other Income Expense | $3,017,000 | $3,834,000 | $1,386,000 | $363,000 |
| Other Non Operating Income Expenses | $3,017,000 | $3,834,000 | $1,386,000 | $363,000 |
| Operating Expense | $30,319,000 | $44,138,000 | $29,682,000 | $34,772,000 |
| General And Administrative Expense | $11,082,000 | $13,192,000 | $13,375,000 | $16,387,000 |
| Interest Expense | - | - | - | $0 |
| Net Non Operating Interest Income Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,736,000 | $-39,807,000 | $-27,872,000 | $-33,945,000 |
| Normalized Income | $-26,736,000 | $-39,807,000 | $-27,872,000 | $-33,945,000 |
| Net Income From Continuing And Discontinued Operation | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Total Operating Income As Reported | $-29,749,000 | $-43,637,000 | $-29,258,000 | $-34,295,000 |
| Net Income Common Stockholders | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Net Income | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Net Income Including Noncontrolling Interests | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Net Income Discontinuous Operations | $253,000 | $-27,000 | $-580,000 | $10,735,000 |
| Net Income Continuous Operations | $-26,736,000 | $-39,807,000 | $-27,872,000 | $-33,945,000 |
| Pretax Income | $-26,732,000 | $-39,803,000 | $-27,872,000 | $-33,932,000 |
| Operating Income | $-29,749,000 | $-43,637,000 | $-29,258,000 | $-34,295,000 |
| Net Interest Income | - | - | - | $0 |
| Special Income Charges | - | - | - | - |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.93 | $-2.78 | $-7.28 |
| Basic EPS | - | $-0.93 | $-2.78 | $-7.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,726,000 | $-43,633,000 | $-29,258,000 | $-34,223,000 |
| Reconciled Depreciation | $23,000 | $4,000 | $0 | $72,000 |
| EBITDA (Bullshit earnings) | $-29,726,000 | $-43,633,000 | $-29,258,000 | $-34,223,000 |
| EBIT | $-29,749,000 | $-43,637,000 | $-29,258,000 | $-34,295,000 |
| Diluted NI Availto Com Stockholders | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Tax Provision | $4,000 | $4,000 | $0 | $13,000 |
| Research And Development | $19,237,000 | $30,946,000 | $16,307,000 | $18,385,000 |
| Selling General And Administration | $11,082,000 | $13,192,000 | $13,375,000 | $16,387,000 |
| Other Gand A | $11,082,000 | $13,192,000 | $13,375,000 | $16,387,000 |
| Diluted Average Shares | - | $42,589,000 | $10,273,000 | $3,186,000 |
| Basic Average Shares | - | $42,589,000 | $10,273,000 | $3,186,000 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-03
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Total Assets | $30,160,000 | $66,905,000 | $97,685,000 | $40,758,000 |
| Total Non Current Assets | $150,000 | $2,468,000 | $1,722,000 | $2,483,000 |
| Other Non Current Assets | $60,000 | $2,262,000 | $1,515,000 | $2,483,000 |
| Current Assets | $30,010,000 | $64,437,000 | $95,963,000 | $38,275,000 |
| Other Current Assets | $1,002,000 | $2,921,000 | $2,656,000 | $2,300,000 |
| Cash Cash Equivalents And Short Term Investments | $29,008,000 | $61,516,000 | $93,253,000 | $30,908,000 |
| Cash And Cash Equivalents | $24,027,000 | $19,926,000 | $30,620,000 | $30,908,000 |
| Restricted Cash | - | $0 | $54,000 | $67,000 |
| Receivables | - | - | $0 | $5,000,000 |
| Non Current Prepaid Assets | - | - | - | $2,483,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | $2,127,000 |
| Accounts Receivable | - | - | - | $173,000 |
| Inventory | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $99,000 | $214,000 | $0 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $99,000 | $0 |
| Current Debt And Capital Lease Obligation | - | $99,000 | $115,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,395,000 | $14,819,000 | $8,950,000 | $9,556,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $1,412,000 | $211,000 |
| Current Liabilities | $2,395,000 | $14,819,000 | $7,538,000 | $9,345,000 |
| Payables And Accrued Expenses | $1,982,000 | $9,872,000 | $3,528,000 | $4,072,000 |
| Payables | $1,041,000 | $2,707,000 | $1,659,000 | $2,386,000 |
| Accounts Payable | $1,041,000 | $2,707,000 | $1,659,000 | $2,386,000 |
| Other Current Liabilities | - | $1,313,000 | - | - |
| Other Non Current Liabilities | - | - | $1,313,000 | - |
| Equity | ||||
| Common Stock Equity | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Total Equity Gross Minority Interest | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Stockholders Equity | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Gains Losses Not Affecting Retained Earnings | $2,000 | $20,000 | $26,000 | $0 |
| Other Equity Adjustments | $2,000 | $20,000 | $26,000 | - |
| Retained Earnings | $-757,653,000 | $-731,170,000 | $-691,336,000 | $-662,735,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $211,000 |
| Other | ||||
| Ordinary Shares Number | $33,323,171 | $14,830,013 | $14,098,888 | $3,229,704 |
| Share Issued | $33,323,171 | $14,830,013 | $14,098,888 | $3,229,704 |
| Tangible Book Value | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Invested Capital | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Working Capital | $27,615,000 | $49,618,000 | $88,425,000 | $28,930,000 |
| Capital Lease Obligations | $0 | $99,000 | $214,000 | $0 |
| Total Capitalization | $27,765,000 | $52,086,000 | $88,735,000 | $31,202,000 |
| Additional Paid In Capital | $785,413,000 | $783,235,000 | $780,044,000 | $693,937,000 |
| Capital Stock | $3,000 | $1,000 | $1,000 | $0 |
| Common Stock | $3,000 | $1,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $0 | $99,000 | $115,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $413,000 | $1,428,000 | $1,645,000 | $2,578,000 |
| Current Accrued Expenses | $941,000 | $7,165,000 | $1,869,000 | $1,686,000 |
| Net PPE | $90,000 | $206,000 | $207,000 | $0 |
| Accumulated Depreciation | $-27,000 | $-4,000 | - | $0 |
| Gross PPE | $117,000 | $210,000 | $207,000 | $0 |
| Machinery Furniture Equipment | $117,000 | $117,000 | - | $0 |
| Other Short Term Investments | $4,981,000 | $41,590,000 | $62,633,000 | $0 |
| Long Term Capital Lease Obligation | - | $0 | $99,000 | $0 |
| Current Provisions | - | $2,107,000 | $2,250,000 | $2,695,000 |
| Other Properties | - | $93,000 | - | - |
| Buildings And Improvements | - | $93,000 | $207,000 | $0 |
| Properties | - | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Duefrom Related Parties Current | - | - | $0 | $5,000,000 |
| Leases | - | - | - | $0 |
| Finished Goods | - | - | - | - |
| Work In Process | - | - | - | - |
| Raw Materials | - | - | - | - |
Fetched: 2026-06-03
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-33,124,000 | $-34,089,000 | $-25,341,000 | $-29,200,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-33,124,000 | $-33,972,000 | $-25,341,000 | $-29,200,000 |
| Cash Flow From Continuing Operating Activities | $-33,124,000 | $-33,972,000 | $-25,341,000 | $-29,200,000 |
| Operating Gains Losses | - | - | - | $-12,636,000 |
| Investing Activities | ||||
| Investing Cash Flow | $37,368,000 | $23,365,000 | $-57,354,000 | $15,667,000 |
| Cash Flow From Continuing Investing Activities | $37,368,000 | $23,365,000 | $-57,354,000 | $15,667,000 |
| Capital Expenditure | - | $-117,000 | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $-143,000 | $-141,000 | $82,394,000 | $1,653,000 |
| Cash Flow From Continuing Financing Activities | $-143,000 | $-141,000 | $82,394,000 | $1,653,000 |
| Repurchase Of Capital Stock | - | $0 | $-360,000 | - |
| Issuance Of Capital Stock | - | $0 | $82,821,000 | $1,681,000 |
| Net Preferred Stock Issuance | - | $0 | $-360,000 | $211,000 |
| Net Common Stock Issuance | - | $0 | $82,821,000 | $1,470,000 |
| Common Stock Issuance | - | $0 | $82,821,000 | $1,470,000 |
| Preferred Stock Issuance | - | - | - | $211,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $24,027,000 | $19,926,000 | $30,674,000 | $30,975,000 |
| Beginning Cash Position | $19,926,000 | $30,674,000 | $30,975,000 | $42,855,000 |
| Changes In Cash | $4,101,000 | $-10,748,000 | $-301,000 | $-11,880,000 |
| Proceeds From Stock Option Exercised | $-143,000 | $-141,000 | $-67,000 | $-28,000 |
| Net Investment Purchase And Sale | $37,368,000 | $23,482,000 | $-62,354,000 | $0 |
| Sale Of Investment | $68,300,000 | $84,000,000 | $0 | $0 |
| Purchase Of Investment | $-30,932,000 | $-60,518,000 | $-62,354,000 | $0 |
| Net PPE Purchase And Sale | $0 | $-117,000 | $0 | - |
| Purchase Of PPE | $0 | $-117,000 | $0 | - |
| Change In Working Capital | $-8,194,000 | $4,999,000 | $60,000 | $2,277,000 |
| Change In Other Current Liabilities | $-99,000 | $-114,000 | $214,000 | $-349,000 |
| Change In Payables And Accrued Expense | $-12,309,000 | $6,012,000 | $-559,000 | $-8,681,000 |
| Change In Payable | $-12,309,000 | $6,012,000 | $-559,000 | $-8,681,000 |
| Change In Account Payable | $-12,309,000 | $6,012,000 | $-559,000 | $-8,681,000 |
| Change In Receivables | $4,214,000 | $-899,000 | $405,000 | $11,210,000 |
| Changes In Account Receivables | $4,214,000 | $-899,000 | $405,000 | $11,210,000 |
| Stock Based Compensation | $2,308,000 | $3,303,000 | $3,305,000 | $4,297,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-1,000 | $1,000 | $0 |
| Amortization Of Securities | $-778,000 | $-2,443,000 | $-255,000 | $0 |
| Depreciation Amortization Depletion | $23,000 | $4,000 | $0 | $72,000 |
| Depreciation And Amortization | $23,000 | $4,000 | $0 | $72,000 |
| Depreciation | $23,000 | $4,000 | $0 | $72,000 |
| Net Income From Continuing Operations | $-26,483,000 | $-39,834,000 | $-28,452,000 | $-23,210,000 |
| Preferred Stock Payments | - | $0 | $-360,000 | - |
| Net Business Purchase And Sale | - | $0 | $5,000,000 | $15,667,000 |
| Sale Of Business | - | $0 | $5,000,000 | $15,667,000 |
| Change In Inventory | - | - | $0 | $97,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $282,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $-12,918,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $0 |
| Effect Of Exchange Rate Changes | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-06-03